尊龙凯时·「中国区」官方网站

2020-11-25 NDA for Y-90 Resin Microspheres of GP(HK) Accepted by NMPA and NDA for Prostate Cancer Imaging RDC Product TLX591-CDx Accepted by FDA

2020-11-13 First Patient Dosed in the Phase 1b Clinical Trial for Sepsis of GP (HK)’s World-Class Innovative Drug STC3141

2020-11-09 Strategic Cooperation with Nanospectra and BlackSwan Expands the Group’s Product Portfolio in Precision Interventional Diagnostics and Treatment

2020-11-01 GP(HK) Enters into A Few Agreements in the Field of Cancer Diagnostics and Treatment Introduce Multiple RDC and Strengthen Strategic Planning and Innovation in Anti-tumor Field

2020-08-11 GP (HK) Announces 2020 Interim Results Profit Attributable to Owners of the Company Rapidly Increases 31.4% to HK$718.5 million With A Focus on Global Expansion and Self-Development Seven Investment, M&A and Cooperation Projects Progress Steadily

2020-07-28 GP (HK) Enters into an Investment Agreement with Revolmmune Introducing the World-Wide Innovative VSV-GPM To Strengthen the Strategic Planning in Tumor Precision Treatment and Tumor Immunotherapy

2020-07-28 GP (HK) Enters into a Capital Subscription and Acquisition Agreement, Acquires the Third-Generation Stent Retriever Contributing to Achieve the Strategic Plan of “Treating the Heart and Brain with the Same Therapeutic Method”

2020-06-01 GP (HK) Enters into an Investment Agreement with eTheRNA Introducing the mRNA Vaccine Platform To Enrich Product Pipeline and Extend the Reach in Multiple Therapeutic Areas

2020-05-19 GP (HK) Announces 2019 Annual Report Three Core Competitiveness Strengthens its Path to an International Pharm Company

2020-05-08 GP (HK)’s World-wide Innovative Drug STC3141 Got Approval for Phase II Clinical Research on COVID-19 ARDS and Phase IB Clinical Research on Sepsis, High-quality Product Contributes to Global Epidemic Prevention & Control

2020-04-28 GP (HK) Obtains Medical Device Registration Certificate for the First Drug Coated Balloon Specified for Vascular Access for Hemodialysis in the PRC Market

2020-04-14 Grandpharma Introduces the Global Innovative Drug CBT001 in Ophthalmology Field